Table 1B.
Characteristics of searches and included studies from reliable systematic reviews of gabapentin (n = 70)
| Review Characteristic | n | (%) | ||
|---|---|---|---|---|
| Specific databases searched | ||||
| PubMed/MEDLINE | 70 | (100%) | ||
| Cochrane | 63 | (90%) | ||
| Embase | 57 | (81%) | ||
| Psych INFO | 14 | (20%) | ||
| CINAHL | 12 | (17%) | ||
| Otheri | 38 | (54%) | ||
| Total number of bibliographic databases searched (median [IQR]) | 4 [3 to 5] | |||
| Additional primary searching beyond bibliographic databases | ||||
| Reference lists of included reports | 60 | (86%) | ||
| Experts in the field or included study authors | 35 | (50%) | ||
| Unpublished/difficult to access literature (e.g., Grey literature, company reports, FDA data, conference abstracts) | 39 | (56%) | ||
| Ongoing studies (e.g., clinical trial registries) | 34 | (49%) | ||
| Types of included studies | For general review | Specifically for harms | ||
| Randomized controlled trial | 69 | (99%) | 0 | (0%) |
| Controlled clinical trial | 12 | (17%) | 4 | (6%) |
| Cohort study | 5 | (7%) | 4 | (6%) |
| Case-control study | 3 | (4%) | 5 | (7%) |
| Case series/report | 4 | (6%) | 2 | (3%) |
| Reviews | 13 | (19%) | 0 | (0%) |
| Surveillance system | 1 | (1%) | 6 | (9%) |
| Other (e.g., Registry studies, cross-sectional studies, medical chart reviews, “noncomparative observational studies with duration ≥ 1 year”) | 4 | (6%) | 2 | (3%) |
| Supplemental searching for data (beyond bibliographic databases, registries, references, and experts) | ||||
| Unpublished studies or data | 22 | (31%) | 3 | (4%) |
| AE reporting systems | 0 | (0%) | 5 | (7%) |
| Hospital or other databases | 0 | (0%) | 1 | (1%) |
| Median [IQR] # studies (total) | participants (total) ii | 34.5 [14 to 78] | 3355 [1204 to 9181] | |||
| Median [IQR] # studies (gabapentin) | participants (gabapentin) iii | 6 [3 to 16] | 420.5 [185 to 1114] | |||
“Other” databases include (alphabetically): Allied and Complementary Medicine Database; Chinese Biological Medical Literature; China National Knowledge Infrastructure; Google Scholar; International Pharmaceutical Abstracts; Latin American and Caribbean Health Sciences Literature; Manual, Alternative and Natural Therapy Index System; National Institute for Health and Care Excellence; NHS databases (Health Economic Evaluation, Centres for Reviews and Dissemination Database of Abstracts of Reviews of Effects); Oxford Pain Relief Database; Pharmline; Reprotox; Scopus; Turning Research Into Practice; Wanfang Data; Web of Science/Science Citation Index
Participant median and IQR derived from 50 reviews that reported the total number of participants
Participant median and IQR derived from 34 reviews that reported the number of gabapentin participants